Theranica’s Nerivio Reaches Coverage Milestone for Half of U.S. Insured

The expansion follows a series of policy updates from national and regional health plans, signaling a shift in how payers approach non-pharmacological interventions. By securing coverage for more than 50% of the approximately 314 million Americans with health insurance, Nerivio moves toward parity with standard prescription migraine medications. This rapid adoption marks one of the fastest reimbursement trajectories for a prescribed therapeutic device, according to the company.

Alon Ironi, CEO and co-founder of Theranica, noted that the milestone allows clinicians to prioritize patient-centric care over economic constraints. For the 39 million Americans living with migraine, the device offers an alternative to systemic drugs by using Remote Electrical Neuromodulation to trigger the body’s pain-inhibitory pathways. Dr. Noah Rosen, director of the Headache Center of Northwell Health, emphasized that integrating evidence-based, FDA-cleared therapies into formularies is essential for reducing the burden of chronic neurological disorders. Patients whose insurance plans have not yet added the device to their coverage may still access the therapy through a dedicated patient assistance program.